A Long-Term Follow-up Study of Subjects With Gaucher Disease Who Previously Received AVR-RD-02

August 28, 2023 updated by: AVROBIO
This is a multicenter, multinational long-term follow-up study to assess the long-term safety and durability of effect of AVR-RD-02 treatment in subjects who previously received AVR-RD-02 treatment (single dose administration).

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

Subjects who received AVR-RD-02 in the preceding treatment study and who meet all eligibility criteria may participate in the AVRO-RD-02-LTF01 study. For individual participating subjects, the Baseline visit for the AVRO-RD-02-LTF01 study will coincide with the subject's last visit in the preceding treatment study, whenever feasible. Subjects will be asked to return for study visits at approximately 6-month intervals for the first 4 years of the study and then annually thereafter for 10 years (for a total follow-up of 14 years in this study), during which time periodic safety and efficacy assessments will be performed to assess measures of safety, engraftment, and clinical response after AVR-RD-02 treatment.

Study Type

Observational

Enrollment (Actual)

4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Calgary Alberta
      • Calgary, Calgary Alberta, Canada, T2M 0L6
        • M.A.G.I.C. Clinic LTD
  • United States
    • Iowa
      • Iowa City, Iowa, United States, 52242
        • University of Iowa
    • New Jersey
      • Hackensack, New Jersey, United States, 07601
        • Hackensack University Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 99 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

To permit longitudinal assessment of safety, efficacy and durability of effect of AVR-RD-02 gene therapy infusion in the AVRO-RD-02-LTF01 study, subjects must have received AVR-RD-02 in a preceding treatment study and agree to comply with the study visit schedule and procedures for AVRO-RD-02-LTF01 for inclusion in the Long-Term Follow-Up study.

Description

Inclusion Criteria:

  • Subject must have been enrolled and received AVR-RD-02 as single dose administration
  • Subject must be willing and able to provide written informed consent for the AVRO-RD-02-LTF01 study in accordance with applicable regulations and guidelines and to comply with all study visits and procedures.

Exclusion Criteria:

  • Subject is currently enrolled in an AVROBIO-sponsored AVR-RD-02 treatment study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Subjects with Gaucher 1 Disease
This is a long-term follow-up study of subjects who previously received AVR-RD-02 (single dose administration) in a preceding treatment study. No investigational product will be administered in this study.
Other: Safety and efficacy assessments
Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention
Other Names:
  • Gene Therapy Intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change from baseline over time in spleen volume as assessed by abdominal Magnetic Resonance Imaging (MRI)
Time Frame: Baseline to Year 15 post gene therapy infusion
Baseline to Year 15 post gene therapy infusion
Baseline over time in liver volume as assessed by abdominal MRI
Time Frame: Baseline to Year 15 post gene therapy infusion
Baseline to Year 15 post gene therapy infusion
Baseline over time in hemoglobin
Time Frame: Baseline to Year 15 post gene therapy infusion
Baseline to Year 15 post gene therapy infusion
Change from Baseline over time in platelet count
Time Frame: Baseline to Year 15 post gene therapy infusion
Baseline to Year 15 post gene therapy infusion
Change from Baseline in plasma lyso-Gb1 levels by liquid chromatography tandem mass spectrometry (LC/MS/MS)
Time Frame: Baseline to Year 15 post gene therapy infusion
Baseline to Year 15 post gene therapy infusion
Incidence of newly-diagnosed malignancy, hematologic disorder, and/or immune related events/immunogenicity
Time Frame: Baseline to Year 15 post gene therapy infusion
Baseline to Year 15 post gene therapy infusion
Number of participants with clinically relevant abnormalities as assessed by vital signs
Time Frame: Baseline to Year 15 post gene therapy infusion
Baseline to Year 15 post gene therapy infusion
Number of participants with clinically relevant abnormalities, as assessed by physical examinations findings
Time Frame: Baseline to Year 15 post gene therapy infusion
Baseline to Year 15 post gene therapy infusion
Number of participants with clinically relevant abnormalities, as assessed by clinical laboratory tests
Time Frame: Baseline to Year 15 post gene therapy infusion
Baseline to Year 15 post gene therapy infusion
Number of participants with clinically relevant abnormalities, as assessed by electrocardiograms (ECGs)
Time Frame: Baseline to Year 15 post gene therapy infusion
Baseline to Year 15 post gene therapy infusion

Secondary Outcome Measures

Outcome Measure
Time Frame
Change from baseline over time in glucocerebrosidase (GCase) GCase enzyme activity level in
Time Frame: Baseline to Year 15 post gene therapy infusion
Baseline to Year 15 post gene therapy infusion
Change from baseline over time in Enzyme Replacement Therapy (ERT) frequency and dosing
Time Frame: Baseline to Year 15 post gene therapy infusion
Baseline to Year 15 post gene therapy infusion
Changes in Gaucher biomarker indices of Gaucher disease in chitotriosidase enzyme activity levels in plasma
Time Frame: Baseline to Year 15 post gene therapy infusion
Baseline to Year 15 post gene therapy infusion
Changes in Gaucher biomarker indices of Gaucher disease in bone marrow burden (BMB) score as assessed by bone MRI
Time Frame: Baseline to Year 15 post gene therapy infusion
Baseline to Year 15 post gene therapy infusion
Changes in Gaucher biomarker indices of Gaucher disease in bone mineral density (BMD) as assessed by dual-energy X-ray absorptiometry (DXA)
Time Frame: Baseline to Year 15 post gene therapy infusion
Baseline to Year 15 post gene therapy infusion
Average Vector Copy Number (VCN) in bone marrow aspirate as assessed by quantitative polymerase chain reaction (qPCR) and/or droplet digital polymerase chain reaction (ddPCR)
Time Frame: Baseline to Year 15 post gene therapy infusion
Baseline to Year 15 post gene therapy infusion
Change from Baseline in anti-GCase total antibodies and subsequent titers by an electrochemiluminescence method
Time Frame: Baseline to Year 15 post gene therapy infusion
Baseline to Year 15 post gene therapy infusion
Changes in Gaucher disease in potential aberrant clonal expansion(s) assessed by performing insertional site analysis (ISA)
Time Frame: Baseline to Year 15 post gene therapy infusion
Baseline to Year 15 post gene therapy infusion
Presence of replication competent lentivirus (RCL)
Time Frame: Baseline to Year 15 post gene therapy infusion
Baseline to Year 15 post gene therapy infusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AVROBIO

Investigators

  • Study Director: Milena Veselinovic, MD, AVROBIO

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 6, 2021

Primary Completion (Actual)

August 21, 2023

Study Completion (Actual)

August 21, 2023

Study Registration Dates

First Submitted

March 23, 2021

First Submitted That Met QC Criteria

April 5, 2021

First Posted (Actual)

April 8, 2021

Study Record Updates

Last Update Posted (Actual)

August 29, 2023

Last Update Submitted That Met QC Criteria

August 28, 2023

Last Verified

September 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AVRO-RD-02-LTF01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

To keep consistent with the current treatment listing

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Type 1 Gaucher Disease

Clinical Trials on Safety and efficacy assessments

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe